Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.985
+$0.065 · +1.66%
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
Regular session
$3.985
+$0.065 · +1.66%
Regular session · ET · Market data may be delayed.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
Day range
Current $3.985
52-week range
Current $3.985
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
38
Expensive
Sentiment
57
Mixed
Risk
76
High Risk
Momentum
42
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.
Day range
Current $3.985
52-week range
Current $3.985
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 147.89K USD | 82.57K USD | 15.53K USD | 15.14K USD | 15.58K USD |
| Gross profit | −147.89K USD | −82.57K USD | −15.53K USD | −15.14K USD | −15.58K USD |
| Research and development | 29.5M USD | 27.19M USD | 20.48M USD | 10.29M USD | 2.53M USD |
| Selling, general, and administrative | 8.08M USD | 6.15M USD | 10.6M USD | 9.32M USD | 6.19M USD |
| Operating expenses | 37.58M USD | 33.34M USD | 31.08M USD | 19.61M USD | 8.72M USD |
| Interest income | 166.38K USD | 283.61K USD | 1.2M USD | 173.86K USD | 4.02K USD |
| Interest expense | 51.29K USD | — | — | 1.24K USD | 100.22K USD |
| Depreciation and amortization | 107.33K USD | 83.9K USD | 15.27K USD | 15.27K USD | 15.26K USD |
| Operating income | −37.73M USD | −33.34M USD | −31.08M USD | −19.61M USD | −8.72M USD |
| Net income | −36.49M USD | −4.79M USD | −27.11M USD | −34.42M USD | −17.27M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 25, 2025 | 1:10 | — | — |
Stock split | Jan 29, 2025 | 1:15 | — | — |
Stock split | Jan 2, 2020 | 1:300 | — | — |
Stock split | Dec 3, 2014 | 307:1,000 | — | — |
Effective Aug 25, 2025
1:10
Effective Jan 29, 2025
1:15
Effective Jan 2, 2020
1:300
Effective Dec 3, 2014
307:1,000
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
